Methods for treating intrapulmonary infections
Inventors
Chandorkar, Gurudatt A. • Huntington, Jennifer A. • Parsons, Tara • Umeh, Obiamiwe C.
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Publication Number
US-10028963-B2
Publication Date
2018-07-24
Expiration Date
Abstract
This disclosure relates to the treatment of intrapulmonary bacterial infections, including treatment of nosocomial pneumonia lung infections with pharmaceutical compositions containing the cephalosporin ceftolozane.
Core Innovation
The invention describes a method of treating pneumonia by repeatedly intravenously administering a pharmaceutical composition to a subject in need thereof. The composition comprises ceftolozane and tazobactam, with ceftolozane administered about once every 8 hours.
The document emphasizes that human Phase 1 epithelial lining fluid (ELF) penetration supports inhibition of Pseudomonas aeruginosa. It states an ELF/plasma AUC ratio for ceftolozane of 0.48 compared to 0.26 for piperacillin in piperacillin/tazobactam.
The invention also includes Phase 1 safety and tolerability information for multiple intravenous doses, together with a dose justification approach using PK/PD simulation. It describes a proposed dosing regimen of 3.0 g IV every 8 hours and relates regimen selection to target pathogen context including Pseudomonas aeruginosa and Enterobacteriaceae.
Claims Coverage
The disclosed independent claim covers repeated intravenous treatment of pneumonia with a ceftolozane/tazobactam pharmaceutical composition, with about once every 8 hours administration and ceftolozane dose as the principal inventive elements.
Repeated intravenous ceftolozane/tazobactam administration for pneumonia
A method of treating pneumonia comprising repeatedly intravenously administering a pharmaceutical composition comprising ceftolozane and tazobactam to a subject in need thereof.
Once every 8 hours ceftolozane dosing with tazobactam
The repeatedly intravenously administering is about once every 8 hours, with the pharmaceutical composition comprising ceftolozane and tazobactam.
Across the independent claim coverage, the core claimed inventive aspect is repeated intravenous administration of a ceftolozane plus tazobactam composition for treating pneumonia, using a dosing cadence of about once every 8 hours.
Stated Advantages
Not explicitly described in patent.
Documented Applications
Treating pneumonia with repeatedly intravenously administered ceftolozane/tazobactam to a subject in need thereof.
Intrapulmonary bacterial infection treatment, especially nosocomial pneumonia, using systemic ceftolozane often in a ceftolozane/tazobactam 2:1 formulation.
Use supported by ELF penetration and PK/PD simulation concepts for inhibiting Pseudomonas aeruginosa in the intrapulmonary setting.
Interested in licensing this patent?